Articles | FAQs | Contact Us


Dr. John Chia

Senior Consultant Medical Oncologist


  • Gynaecological cancers

Medical Conditions Treated:

  • Ovarian Cancer
  • Endometrial Cancer
  • Cervical cancers.
  • Colorectal cancers, including rare tumors such as melanoma, uterine
  • Sarcomas, and germ cell tumours


English, Mandarin


MBBS (UK), MRCP (UK), FRCP (Edin), FACP (USA), Diplomate American Board of Internal Medicine and Medical Oncology

Professional Profile:

Dr John Chia has extensive experience in the field of immunotherapy for solid cancers. He graduated with double distinctions in Medicine and Surgery from the National University of Singapore in 1999, and subsequently obtained his Membership of the Royal College of Physicians in Edinburgh in 2002. Dr Chia has played a key role in the development and leadership of numerous immunotherapy clinical trials in Singapore, and has worked with leading experts in the field such as Professor Malcom Brenner and Professor Stan Kaye.

In addition to his clinical work, Dr Chia is also heavily involved in clinical trial research, and has developed numerous research protocols and trials for various cancers including ovarian, cervical, colorectal, nasopharyngeal, and breast cancer. He has published extensively in leading international journals, and holds numerous local and international research grants.

Dr Chia is a former Chief of the Gynaecology Oncology service in the Division of Medical Oncology, National Cancer Centre, and a founding board member of the Gynecologic Cancer Group Singapore. He is also a council member of the College of Clinician Scientists, Academy of Medicine, and Adjunct Associate Professor at DUKE-NUS. Dr Chia sits on the Scientific Board of the International Aspirin Foundation, and lectures widely at international conferences.

Locally, Dr Chia has contributed significantly to cancer management guidelines and awareness efforts in Singapore, and is a member of various committees and societies dedicated to improving cancer care and promoting immunotherapy access.